Table 4.

Relative risk of high‐grade cervical disease according to age group

HPV test result	Relative risk of CIN2+ (95% CI)	P value
Women 30–34 years old
HPV16(+) versus HPV16(−)	90.0 (4.00–2023.39)	0.005
HPV18/45(+) versus HPV18/45(−)	(no cases)
HPV16/18/45(+) versus other HR‐HPV(+)	7.2 (0.59–87.77)	0.122
Women 35–39 years old
HPV16(+) versus HPV16(−)	1.8 (0.17–19.25)	0.613
HPV18/45(+) versus HPV18/45(−)	2.9 (0.55–14.85)	0.214
HPV16/18/45(+) versus other HR‐HPV(+)	3.2 (0.64–16.38)	0.155
Women 40–44 years old
HPV16(+) versus HPV16(−)	6.7 (0.68–52.90)	0.107
HPV18/45(+) versus HPV18/45(−)	1.1 (0.10–12.36)	0.923
HPV16/18/45(+) versus other HR‐HPV(+)	5.08 (0.48–54.02)	0.178
Women ≥35 years old
HPV16(+) versus HPV16(−)	6.2 (0.73–53.4)	0.095
HPV18/45(+) versus HPV18/45(−)	1.0 (0.10–11.09)	0.973
HPV16/18/45(+) versus other HR‐HPV(+)	3.7 (0.52–25.77)	0.192
Women (all ages)
HPV16(+) versus HPV16(−)	6.5 (2.21–19.64)	0.001
HPV18/45(+) versus HPV18/45(−)	1.4 (0.46–4.09)	0.568
HPV16/18/45(+) versus other HR‐HPV(+)	4.2 (1.57–11.47)	0.004

CIN2+, cervical intraepithelial neoplasia grade 2 or worse; HPV, human papilloma virus; HR‐HPV, high‐risk HPV types; Other HR‐HPV(−), HPV DNA test negative for high‐risk types other than HPV 16/18/45; Other‐HR HPV(+), HPV DNA test positive for high‐risk types other than HPV 16/18/45; HPV 16(+), HPV DNA test positive for HPV 16; HPV 18/45(+), HPV DNA test positive for HPV 18; HPV 16/18/45(+), HPV DNA test positive for HPV 16, HPV 18, and HPV 45.